Jing Xiang-Yi, Zhang Yong-Ling, Zhen Li, Li Yan-Lin, Li Dong-Zhi
Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
J Obstet Gynaecol. 2022 Oct;42(7):2935-2940. doi: 10.1080/01443615.2022.2114324. Epub 2022 Aug 23.
The aim of this study was to present prenatal ultrasound findings, molecular testing results and pregnancy outcomes of cases with 22q11.2 deletion (del22q11.2) diagnosed prenatally. A total of 76 foetuses were included. All cases were diagnosed by using chromosomal microarray analysis. Data on prenatal diagnosis, ultrasound findings, pregnancy outcomes and inheritance of del22q11.2 were reviewed. Congenital heart defects (CHDs) were the most common indications (47/76, 61.8%) for prenatal testing and were isolated in 52.6% (40/76). The constitution of CHDs comprised predominantly of conotruncal defects (61.7%; 29/47). Other cardiac anomalies were encountered in 38.3% (18/47) of cases. Extracardiac findings, including unilateral multicystic dysplastic kidney, clubfoot, increased nuchal translucency, intrauterine growth retardation and polyhydramnios, were found in 31.6% (24/76) of cases, and were combined with CHDs in 7 cases. Twelve cases had normal sonographic scans at the time of prenatal diagnosis. Foetal CHDs, especially conotruncal defects, are the most predictive association with del22q11.2. The information about del22q11.2 should also be part of the contents in comprehensive pre-test counselling even for those who are referred for diagnostic testing with foetal extracardiac findings.Impact statement 22q11.2 deletion (del22q11.2) is the most common microdeletion syndrome in humans. At present, the main indications for prenatal testing for del22q11.2 are pregnancies of abnormal sonographic findings, especially foetal congenital heart defects. Many extracardiac malformations, including some lethal or mildly non-specific ones, could be associated with foetal del22q11.2. There were also del22q11.2 foetuses had normal sonographic scans at the time of prenatal diagnosis. The information about del22q11.2 should also be part of the contents in comprehensive pre-test counselling even for those who are referred for diagnostic testing with indications other than foetal cardiac anomalies.
本研究旨在呈现产前诊断为22q11.2缺失(del22q11.2)病例的产前超声检查结果、分子检测结果及妊娠结局。共纳入76例胎儿。所有病例均采用染色体微阵列分析进行诊断。回顾了关于del22q11.2的产前诊断、超声检查结果、妊娠结局及遗传情况的数据。先天性心脏缺陷(CHD)是产前检测最常见的指征(47/76,61.8%),其中孤立性CHD占52.6%(40/76)。CHD的构成主要为圆锥动脉干畸形(61.7%;29/47)。38.3%(18/47)的病例还存在其他心脏异常。31.6%(24/76)的病例发现了心外表现,包括单侧多囊性发育不良肾、马蹄内翻足、颈项透明层增厚、胎儿生长受限及羊水过多,其中7例合并CHD。12例在产前诊断时超声扫描正常。胎儿CHD,尤其是圆锥动脉干畸形,是与del22q11.2最具预测性的关联。即使对于那些因胎儿心外表现而转诊进行诊断检测的患者,关于del22q11.2的信息也应成为综合检测前咨询内容的一部分。影响声明22q11.2缺失(del22q11.2)是人类最常见的微缺失综合征。目前,del22q11.2产前检测的主要指征是超声检查结果异常的妊娠,尤其是胎儿先天性心脏缺陷。许多心外畸形,包括一些致死性或轻度非特异性畸形,可能与胎儿del22q11.2有关。也有产前诊断时超声扫描正常的del22q11.2胎儿。即使对于那些因胎儿心脏异常以外的指征而转诊进行诊断检测的患者,关于del22q11.2的信息也应成为综合检测前咨询内容的一部分。